FILING BY "EXPRES	S MAIL" UNDER 37 CFR 1.10
Express Mail Label Number	Date of Deposit

Form PTC-1390-MOD (REV 10-96) TRANSMITTAL LETTER		Department of Commerce Patent and Trademark Office	ATTORNEY'S DOCKET NUMBER 33647-US-PCT								
		HE UNITED STATES	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)								
	DESIGNATED/ELECTED O	FFICE (DO/EO/US)									
	CONCERNING A FILING UN	NDER 35 U.S.C. 371	DATE OLAMATO								
	NATIONAL APPLICATION NO. P2005/001362	INTERNATIONAL FILING DATE 10 February 2005 (10.02.05)	PRIORITY DATE CLAIMED 11 February 2004 (11.02.04)								
	OF INVENTION	10 Tebruary 2000 (10.02.00)	111 001001 1 1 1 1 1 1 1 1 1 1 1 1 1 1								
CHEMO	CHEMOKINE RECEPTOR ANTAGONISTS										
APPLICANT(S) FOR DO/EO/US HERSPERGER ET AL.											
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:											
1. ⊠ 2. □ 3. □	This is a FIRST submission of items con This is a SECOND or SUBSEQUENT su This express request to begin national examination until the expiration of the ap	ibmission of items concerning a filing un xamination procedures (35 U.S.C. 371(f)) at any time rather than delay								
4. 🛛	A proper Demand for International Prelin	ninary Examination was made by the 19	th month from the earliest claimed priority								
5. 🏻	date. A copy of the International Application as	s filed (35 U.S.C. 371(c)(2))									
• •	 a. ☐ is transmitted herewith (required b. ☒ has been transmitted by the Inte 	only if not transmitted by the Internation	ial Bureau). เลิเ								
	c. is not required, as the application	n was filed in the United States Receivin	g Office (RO/US).								
6. □ 7. ⊠	A translation of the International Application	ational Application under PCT Article 19	(35 U.S.C.371(c)(3)).								
23	a. are transmitted herewith (require	ed only if not transmitted by the Internation	onal Bureau).								
	c. 🔲 have not been made; however, t	the time limit for making such amendmen	nts has NOT expired.								
8. 🗌	d. A translation of the amendments to the control of the amendments.	t be made. claims under PCT Article 19 (35 U.S.C. 3	371 (c)(3)).								
9. 🔲	 An executed Declaration and Power of A 	Attorney (original or copy) (35 U.S.C. 371	1(c)(4)).								
10.	A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).										
Items 1	1. to 16. below concern document(s) o	r information included.									
11. 🛛	An Information Disclosure Statement un	der 37 CFR 1.97 and 1.98.									
12.	An assignment document for recording.	A separate cover sheet in compliance v	with 37 CFR 3.28 and 3.31 is included.								
13. 🛛	A FIRST preliminary amendment.										
	A SECOND or SUBSEQUENT prelimina	ary amendment.									
14. 🛚	An Application Data Sheet under 37 CF	R 1.76.									
15. 🗌	A substitute specification.										
16. 🔲	A change of power of attorney and/or ac	ddress letter.									
17.	A computer-readable form of the sequen	nce listing in accordance with PCT Rule	13ter.2 and 37 CFR 1.821-1.825.								
18. 🗌	A second copy of the published International Application under 35 U.S.C. 154(d)(4).										
19. 🗌	A second copy of the English language	translation of the International applicatio	n under 35 U.S.C. 154(d)(4).								
20. 🛛	Other items or information: Unexecuted Declaration and Power of Attorney										

U.S. APPLICATION NO.	(if known, see 37 CFR 1.5)		NATIONAL APPLICATION NO. Γ/E P2005/001362			33647-US-	PCT			
The following fee	es are submitted:						CALCULAT	ION	S PTO USE	
							ONLY			
21. 🖾 Basid	national fee					\$300				
22. Examination Fee							:			
☐ If International preliminary examination report was prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4)						\$				
·	• •					\$200				
. All ot	ner situations					\$200				
23. Search fee										
If Search fee (37 CFR 1.445(a)(2)) has been paid on the international										
application to the USPTO as an International Searching Authority \$ ☑ If International Search Report was prepared and provided to the Office \$400						\$400				
☐ All ot	All other situations									
		TOTAL OF	21, 22 AND 23 =				\$ 90	0		
			n paper over 100 sheets (-		
program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.										
Total Sheets	Extra sheets		ch additional 50 or fractio	n	R	ATE				
- 100 =	/50 =	thereof (round	d up to a whole number) 0	×	\$	250	\$	╅		
0 1 1 101	AA COOK STANDARD						_	1		
	30 for furnishing the earliest claimed price						\$	┸		
CLAIMS		R FILED	NUMBER EXTRA	X	RAT	E 50	\$	4		
Total claims Independent cla	ims 3	- 20 =	0	x	<u>\$</u>	200	\$	╅		
	ENDENT CLAIM(S)	(if applicable)		+	\$	360	\$	1		
Deduction of 1/2) factiling by analysis	osis, if analiani	TOTAL OF ABOVE ble. Verified Small Entity				\$ 90	<u>•</u>		
	FR 1.9, 1.27, 1.28).	питу, п аррпса	ble. Verified Small Entity	Statem	ieni mus	st also be	\$			
						TOTAL =	\$ 90	0_		
	of \$130 for furnishing priority date (37 CFF		ranslation later than	30 mon	iths from	n the	\$	ı		
	· · · · · · · · · · · · · · · · · · ·					AL FEE =	\$ 90	ō		
	g the enclosed assig te cover sheet (37 Cl		R 1.21(h)). The assignments	ent mus	st be ac	companied	\$			
ру ап арргорпат	e cover sileer (57 Ci	1 13 3.20, 3.51)		FEES	ENC	LOSED =	\$ 90	0		
							Amount t	o !	\$	
							be: refunde charge		\$	
a. 🗌 A chec	k in the amount of \$		to cover the above fee	es is en	closed.		onongo	<u> </u>		
	· -		134 in the name of Novart			nt of \$900 to	cover the abo	ve fe	ees. A	
	te copy of this form i					., .,				
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.										
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.										
	_			77	A	/ //			f	
Send all correspondence to the address associated with Customer No. 001095, which is currently:										
Novartis				r J. Wa		nte			•	
Corporate Intellectual Property Reg. No. 43,228										
One Health Plaza, Building 104 (862) 778-7951 East Hanover, NJ 07936-1080										
	,								ļ	